Blood cancers

AML in 2019 and beyond: challenges amid new promise

The treatment landscape for acute myeloid leukaemia (AML) – and hopefully patient outcomes – are expected to change significantly over the next couple of years. Haematologist Associate Professor Andrew Wei, from Monash University and head of leukaemia research at The Alfred Hospital, told the limbic the fact that the main chemotherapy drugs in use were discovered ...

Already a member?

Login to keep reading.

© 2021 the limbic